Diagnosis and Pharmacotherapy of Chronic Obstructive Pulmonary Disease

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The user is experiencing insomnia after starting finasteride and is seeking solutions without quitting the medication. Suggestions include trying ZMA, maintaining consistent sleep habits, and considering other sleep aids like Nytol or melatonin.

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.